Stem Cells, Vol 12, 440-455, Copyright © 1994 by AlphaMed Press

REVIEWS

A family of ligands for the TNF receptor superfamily

D Cosman
Department of Molecular Biology, Immunex Research and Development Corporation, Seattle, Washington 98101.

Recent progress in the definition of molecules involved in immune regulation has led to the discovery of a number of type I membrane glycoproteins with a distinctive, cysteine-rich, repetitive domain structure within their extracellular regions. Because the prototype members of this family are receptors for cytokines (tumor necrosis factor [TNF] and nerve growth factor [NGF]), it was expected that the ligands for the other receptors would possess cytokine-like activities. This prediction has been fulfilled by the cloning of cDNA encoding a series of type II membrane glycoproteins, with homology to TNF, that bind to, and signal through, their cognate receptors. While the biological role of some of these ligand-receptor pairs remains obscure, at least two members of the family, CD40 and Fas, have proven their importance. The human X-linked immunodeficiency, hyper IgM syndrome, is the result of mutations in the CD40 ligand gene, and the Fas and Fas ligand genes are mutated in two mouse strains, lpr and gld, that develop autoimmune disease. These findings, together with other evidence, point to key roles of CD40/CD40 ligand interactions in immune activation, particularly in T-dependent B cell responses, and of Fas/Fas ligand in apoptosis and peripheral tolerance. These molecules, as well as the other ligands of the family, share the property of costimulation of T cell proliferation and are all expressed by activated T cells. More detailed analysis of the expression patterns of ligands and receptors on lymphocyte subpopulations will be necessary to define their different roles in immune activation and suppression.

This article has been cited by other articles:

				A. E. Field, S. Wagage, S. M. Conrad, and D. M. Mosser Reduced Pathology following Infection with Transgenic Leishmania major Expressing Murine CD40 Ligand Infect. Immun., June 1, 2007; 75(6): 3140 - 3149. [Abstract] [Full Text] [PDF]

				H. Matsubara, Y. Mizutani, F. Hongo, H. Nakanishi, Y. Kimura, S. Ushijima, A. Kawauchi, T. Tamura, T. Sakata, and T. Miki Gene therapy with TRAIL against renal cell carcinoma. Mol. Cancer Ther., September 1, 2006; 5(9): 2165 - 2171. [Abstract] [Full Text] [PDF]

				T. Mori, A. Oguro, T. Ohtsu, and Y. Nakamura RNA aptamers selected against the receptor activator of NF-{kappa}B acquire general affinity to proteins of the tumor necrosis factor receptor family Nucleic Acids Res., November 23, 2004; 32(20): 6120 - 6128. [Abstract] [Full Text] [PDF]

				S. S. Ahuja, S. Zhao, T. Bellido, L. I. Plotkin, F. Jimenez, and L. F. Bonewald CD40 Ligand Blocks Apoptosis Induced by Tumor Necrosis Factor {alpha}, Glucocorticoids, and Etoposide in Osteoblasts and the Osteocyte-Like Cell Line Murine Long Bone Osteocyte-Y4 Endocrinology, May 1, 2003; 144(5): 1761 - 1769. [Abstract] [Full Text] [PDF]

				S. M. Propst, K. Estell, and L. M. Schwiebert CD40-mediated Activation of NF-kappa B in Airway Epithelial Cells J. Biol. Chem., September 27, 2002; 277(40): 37054 - 37063. [Abstract] [Full Text] [PDF]

				T. S. Griffith, J. M. Fialkov, D. L. Scott, T. Azuhata, R. D. Williams, N. R. Wall, D. C. Altieri, and A. D. Sandler Induction and Regulation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand-mediated Apoptosis in Renal Cell Carcinoma Cancer Res., June 1, 2002; 62(11): 3093 - 3099. [Abstract] [Full Text] [PDF]

				M. Suresh, G. Lanier, M. K. Large, J. K. Whitmire, J. D. Altman, N. H. Ruddle, and R. Ahmed Role of Lymphotoxin {alpha} in T-Cell Responses during an Acute Viral Infection J. Virol., March 19, 2002; 76(8): 3943 - 3951. [Abstract] [Full Text] [PDF]

				G. L. Sica, G. Zhu, K. Tamada, D. Liu, J. Ni, and L. Chen RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF-{kappa}B Blood, May 1, 2001; 97(9): 2702 - 2707. [Abstract] [Full Text] [PDF]

				A. Chuntharapai, K. Dodge, K. Grimmer, K. Schroeder, S. A. Marsters, H. Koeppen, A. Ashkenazi, and K. J. Kim Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 J. Immunol., April 15, 2001; 166(8): 4891 - 4898. [Abstract] [Full Text] [PDF]

				R. Wang, L. Zhang, X. Zhang, J. Moreno, X. Luo, M. Tondravi, and Y. Shi Differential Regulation of the Expression of CD95 Ligand, Receptor Activator of Nuclear Factor-{{kappa}}B Ligand (RANKL), TNF-Related Apoptosis-Inducing Ligand (TRAIL), and TNF-{{alpha}} During T Cell Activation J. Immunol., February 1, 2001; 166(3): 1983 - 1990. [Abstract] [Full Text] [PDF]

				T. S. Griffith, R. D. Anderson, B. L. Davidson, R. D. Williams, and T. L. Ratliff Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis J. Immunol., September 1, 2000; 165(5): 2886 - 2894. [Abstract] [Full Text] [PDF]

				P. A. Moore, O. Belvedere, A. Orr, K. Pieri, D. W. LaFleur, P. Feng, D. Soppet, M. Charters, R. Gentz, D. Parmelee, et al. BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator Science, July 9, 1999; 285(5425): 260 - 263. [Abstract] [Full Text]

				S. Mori, K. Murakami-Mori, S. Nakamura, A. Ashkenazi, and B. Bonavida Sensitization of AIDS-Kaposi's Sarcoma Cells to Apo-2 Ligand-Induced Apoptosis by Actinomycin D J. Immunol., May 1, 1999; 162(9): 5616 - 5623. [Abstract] [Full Text] [PDF]

				T. S. Griffith, C. T. Rauch, P. J. Smolak, J. Y. Waugh, N. Boiani, D. H. Lynch, C. A. Smith, R. G. Goodwin, and M. Z. Kubin Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies J. Immunol., March 1, 1999; 162(5): 2597 - 2605. [Abstract] [Full Text] [PDF]

				A. Druilhe, B. Wallaert, A. Tsicopoulos, J.-R. L. e Silva, I. Tillie-Leblond, A.-B. Tonnel, and M. Pretolani Apoptosis, Proliferation, and Expression of Bcl-2, Fas, and Fas Ligand in Bronchial Biopsies from Asthmatics Am. J. Respir. Cell Mol. Biol., November 1, 1998; 19(5): 747 - 757. [Abstract] [Full Text]

				K. Fuller, B. Wong, S. Fox, Y. Choi, and T. J. Chambers TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts J. Exp. Med., September 7, 1998; 188(5): 997 - 1001. [Abstract] [Full Text] [PDF]

				J. J. Peschon, D. S. Torrance, K. L. Stocking, M. B. Glaccum, C. Otten, C. R. Willis, K. Charrier, P. J. Morrissey, C. B. Ware, and K. M. Mohler TNF Receptor-Deficient Mice Reveal Divergent Roles for p55 and p75 in Several Models of Inflammation J. Immunol., January 15, 1998; 160(2): 943 - 952. [Abstract] [Full Text] [PDF]

				M. A. Degli-Esposti, P. J. Smolak, H. Walczak, J. Waugh, C.-P. Huang, R. F. DuBose, R. G. Goodwin, and C. A. Smith Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family J. Exp. Med., October 6, 1997; 186(7): 1165 - 1170. [Abstract] [Full Text] [PDF]

				S.-S. Cha, B.-J. Sung, Y.-A Kim, Y.-L. Song, H.-J. Kim, S. Kim, M.-S. Lee, and B.-H. Oh Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity J. Biol. Chem., September 29, 2000; 275(40): 31171 - 31177. [Abstract] [Full Text] [PDF]